This Is MS Multiple Sclerosis Knowledge & Support Community

Positive top-line results in phase III Daclizumab high-Yield process study in MS

Biogen Idec and AbbVie ABBV announced positive top-line results from the Phase 3 DECIDE clinical trial, designed to evaluate the superiority of once-monthly, subcutaneous daclizumab high-yield process (DAC HYP) when compared to intramuscular interferon beta-1a (IFN β-1a), as a potential treatment for relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS). Results showed that DAC HYP was superior on the study’s primary endpoint, demonstrating a statistically significant 45 percent reduction in annualized relapse rate (ARR) compared to IFN β-1a (p<0.0001)....... Read More - http://www.ms-uk.org/zenapax

MSUK wrote:Positive top-line results in phase III Daclizumab high-Yield process study in MS

Biogen Idec and AbbVie ABBV announced positive top-line results from the Phase 3 DECIDE clinical trial, designed to evaluate the superiority of once-monthly, subcutaneous daclizumab high-yield process (DAC HYP) when compared to intramuscular interferon beta-1a (IFN β-1a), as a potential treatment for relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS). Results showed that DAC HYP was superior on the study’s primary endpoint, demonstrating a statistically significant 45 percent reduction in annualized relapse rate (ARR) compared to IFN β-1a (p<0.0001)....... Read More - http://www.ms-uk.org/zenapax

Hmmm..another monoclonal antibody(no long term side effects known) that hangs its hat on a reduction of white matter lesions (which don't correlate with MS symptoms) and elevates liver enzymes 6 times above normal!! Another Tysabri in the making?